Zovegalisib Granted Breakthrough Therapy Designation by FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer February 9, 2026
DATROWAY® Granted Priority Review in the US in 1L Metastatic TNBC Patients Who Are Not Candidates for Immunotherapy February 9, 2026
Multiple Sites Activated for Ph 1b/2 Trial of AMXT 1501 and DFMO in Patients with solid tumors including Breast Cancer and Melanoma February 9, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to Evorpacept in Combination with Ziihera in HER2+ve Breast Cancer February 1, 2026
Trodelvy® Added as Preferred Regimen Within 1L Metastatic TNBC in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) February 1, 2026
NEJM Publishes Ph 3 ASCENT-04/KEYNOTE-D19 Results of Trodelvy + Keytruda in 1L PD-L1+ Metastatic TNBC January 25, 2026
ENHERTU + Pertuzumab Type II Variation Application Validated in the EU in 1L HER2+ve Metastatic Breast Cancer January 25, 2026
Bio-Sourcing, Zerion Pharma to Collaborate on First HER2 Oral Monoclonal Antibody for Breast Cancer January 18, 2026
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer January 18, 2026
FDA “Study May Proceed” Letter for (Z)-Endoxifen IND Application for Metastatic Breast Cancer Received January 11, 2026
Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study Completed January 11, 2026
Athira Pharma Announces Exclusive License to Lasofoxifene Ph 3 Development Program for Metastatic Breast Cancer Candidate and Financing for up to $236M December 30, 2025
Pidnarulex (CX-5461) – Enhertu combo to be evaluated in Ph 1b trial in HER2-positive and HER2-low solid tumors and breast cancer patients December 30, 2025
Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer December 30, 2025
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic December 22, 2025
Athira Pharma Announces Exclusive License to Lasofoxifene Ph 3 Development Program for Metastatic Breast Cancer Candidate and Financing for up to $236M December 22, 2025
Preliminary Analysis Shows 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 December 22, 2025
IND Application to Initiate a Ph 1 Trial of ABP-102/CT-P72 for HER2-positive Cancers submitted to the US FDA December 22, 2025
DATROWAY® Type II Variation Application Validated in the EU for Patients with 1L Metastatic, IO-ineligible TNBC December 22, 2025
